AstraZeneca Announces Approval Of Koselugo In Canada
(RTTNews) - AstraZeneca (AZN, AZN.L, ZEG.DE, AZN.ST) said Alexion, AstraZeneca Rare Disease's Koselugo has been approved in Canada for the treatment of adult patients with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas. The approval by Health Canada was based on positive results from KOMET.
Koselugo has been recently approved in the US, EU, Japan and other countries for the treatment of adult patients with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas based on data from the KOMET Phase III trial, and additional regulatory reviews are ongoing.
In pre-market trading on NYSE, AstraZeneca shares are down 2.78 percent to $188.92.
For More Such Health News, visit rttnews.com.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.